Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Invyncible vs Ro

By GLP-1 ScorecardUpdated

InvyncibleFactor scores not reassessed.
Site position #270

Lower score

Ro
Site position #37

Higher score

Score comparison

Ro has the higher recorded score — 80.2/100 to 63.6/100.

Ro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Ro is worth comparing for branded access and insurance help, but the membership price is only one part of the bill.

Before you choose

Ro does not publish a semaglutide price, so its Ro review sets out what it does disclose, while the Invyncible review explains the conditions attached to Invyncible's figure. The semaglutide cost page compares published rates across the field. Ask Ro for a written total before treating either one as the cheaper choice.

If neither one fits, Invyncible vs Sesame Care and JumpstartMD vs Ro compare each of them with another graded program, and the list of alternatives to Invyncible ranks the programs closest to Invyncible on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the Collective review covers one graded close to these two, at 71.6/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueRo +23
45
68
Dose & formulationRo +8
78
86
Clinical oversightRo +16
70
86
Labs & monitoringRo +30
52
82
FulfillmentRo +11
73
84
Contract termsRo +3
77
80
Invyncible · top barRo · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricInvyncibleRo
WeighScore63.6/10080.2/100
GradeCB−
Site position#270#37
Semaglutide$145 starter program; supply length and refill cost need confirmationVaries (branded medication plus separate membership)
Tirzepatide$179 per 4-week starter program (2.5 mg weekly, compounded glycine + B12)Varies (branded medication plus separate membership)
CoverageVaries by formulation; glycine/B12 programs exclude AR, CA, IN, MN, OR and SCMulti-state
Brand-name accessYesYes
Oral / sublingualYesYes
Invyncible

Site position #270 · C

Factor scores not reassessed.

Strengths

  • Six pharmacies named with contact details
  • Patients can request a prescription copy or nominate a pharmacy
  • Public catalogs distinguish compounded products, brands and oral options
  • Refills are not automatic; payment is finalized only after physician approval

What to consider

  • Program amounts are not universal monthly prices; dose and formulation can change cost
  • Shipping cost not established on the reviewed program pages
  • State exclusions differ by formulation
  • Compounded medications are not FDA-approved
Ro

Site position #37 · B−

Strengths

  • Brand-name access + insurance support
  • Oral options
  • Current pricing separates membership from medication charges

What to consider

  • Membership starts at $39 for the first month, then $74–149 per month depending on term; the $74 rate requires annual prepayment
  • Medication is extra; the total depends on the selected drug and payment arrangement
  • Membership cancellation requires at least 48 hours before renewal; paid membership fees are described as nonrefundable

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard